• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Schrodinger Inc.

    5/7/25 4:25:07 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    S-8 1 sdgr-formsx8xinducementpla.htm S-8 Document

    As filed with the Securities and Exchange Commission on May 7, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    Schrödinger, Inc.
    (Exact Name of Registrant as Specified in Its Charter)
     

       
    Delaware 95-4284541
    (State or Other Jurisdiction of
    Incorporation or Organization)
     
    (I.R.S. Employer
    Identification No.)
      
    1540 Broadway, 24th Floor
    New York, New York
     10036
    (Address of Principal Executive Offices) (Zip Code)
    2021 Inducement Equity Incentive Plan, as amended
    (Full Title of the Plan)
    Ramy Farid, Ph.D.
    President and Chief Executive Officer
    Schrödinger, Inc.
    1540 Broadway, 24th Floor
    New York, New York 10036
    (Name and Address of Agent For Service)
    (212) 295-5800
    (Telephone Number, Including Area Code, of Agent For Service)



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☒ Accelerated filer ☐
        
    Non-accelerated filer ☐ Smaller reporting company ☐
        
        Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ 




    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Item 1. Plan Information.
    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).
    Item 2. Registrant Information and Employee Plan Annual Information.
    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents listed below (File No. 001-39206), which are on file with the Commission, are incorporated in this registration statement by reference:
    (a) The registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on February 26, 2025, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the registrant’s definitive proxy statement for the 2025 Annual Meeting of Stockholders;
    (b) The registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 as filed with the Commission on May 7, 2025;
    (c) The registrant’s Current Reports on Form 8-K as filed with the Commission on March 10, 2025 and April 11, 2025;
    (d) The description of the securities contained in the registrant’s registration statement on Form 8-A filed with the Commission on January 31, 2020, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.3 to the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Commission on March 4, 2021, including any amendments or reports filed for the purpose of updating such description.
    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.




    Item 4. Description of Securities.
    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”), permits a corporation to eliminate or limit the personal liability of its directors or officers to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law (in the case of a director), obtained an improper personal benefit or in any action by or in the right of the corporation (in the case of an officer). No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective. The registrant’s certificate of incorporation provides that, to the fullest extent permitted by the DGCL, no director or officer shall be personally liable to the registrant (in the case of directors), the registrant’s stockholders (in the case of directors and officers) for monetary damages for any breach of fiduciary duty as a director or officer.
    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit, or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.
    The registrant’s certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the registrant), by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust, or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit, or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
    The registrant’s certificate of incorporation also provides that the registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the registrant to procure a judgment in the registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee, or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust, or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including



    attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
    In addition, the registrant has entered into indemnification agreements with all of the registrant’s executive officers and directors. In general, these agreements provide that the registrant will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of the registrant or in connection with his or her service at the request of the registrant for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director.
    The registrant maintains a general liability insurance policy that covers certain liabilities of the registrant’s directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
    Item 7. Exemption from Registration Claimed.
    Not applicable.
    Item 8. Exhibits.
    The following exhibits are incorporated herein by reference:
     
    NumberDescription
     
    4.1
    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Registrant’s Quarterly Report on Form 10-Q (File No. 001-39206) filed with the Securities and Exchange Commission on July 31, 2024).
     
    4.2
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K (File No. 001-39206) filed with the Securities and Exchange Commission on April 13, 2023).
     
    5.1*
    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.
     
    23.1*
    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).
     
    23.2*
    Consent of KPMG LLP, independent registered public accounting firm.
    24.1*
    Power of attorney (included on the signature page of this registration statement).
    99.1*
    2021 Inducement Equity Incentive Plan, as amended.
     
    107*
    Filing Fee Table.

    *Filed herewith




    Item 9. Undertakings.
    1. Item 512(a) of Regulation S-K. The undersigned registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
    provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2. Item 512(b) of Regulation S-K. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3. Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on this 7th day of May, 2025.
    SCHRÖDINGER, INC.

    By:    /s/ Ramy Farid                                     
        Ramy Farid, Ph.D.
        President and Chief Executive Officer





    POWER OF ATTORNEY AND SIGNATURES
    We, the undersigned officers and directors of Schrödinger, Inc., hereby severally constitute and appoint Ramy Farid, Geoffrey Porges and Yvonne Tran, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Schrödinger, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Ramy Farid                                
    Ramy Farid, Ph.D.
    President and Chief Executive Officer, Director (Principal Executive Officer)May 7, 2025
    /s/ Geoffrey Porges                        
    Geoffrey Porges, MBBS
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)
    May 7, 2025
    /s/ Jenny Herman                           
    Jenny Herman
    Senior Vice President, Finance and Corporate Controller
    (Principal Accounting Officer)
    May 7, 2025
    /s/ Michael Lynton                          
    Michael Lynton
    DirectorMay 7, 2025
    /s/ Jeffrey Chodakewitz                  
    Jeffrey Chodakewitz, M.D.
    DirectorMay 7, 2025
    /s/ Richard Friesner                         
    Richard Friesner, Ph.D.
    DirectorMay 7, 2025
    /s/ Gary Ginsberg                            
    Gary Ginsberg
    DirectorMay 7, 2025
    /s/ Rosana Kapeller-Libermann      
    Rosana Kapeller-Libermann, M.D. Ph.D.
    DirectorMay 7, 2025
    /s/ Arun Oberoi                               
    Arun Oberoi
    DirectorMay 7, 2025
    /s/ Gary Sender                               
    Gary Sender
    DirectorMay 7, 2025
    /s/ Nancy Thornberry                     
    Nancy Thornberry
    DirectorMay 7, 2025
    /s/ Bridget van Kralingen       
    Bridget van Kralingen
    DirectorMay 7, 2025


    Get the next $SDGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    11/19/2021$82.00 → $49.00Overweight → Equal-Weight
    Morgan Stanley
    11/19/2021$87.00Overweight
    Piper Sandler
    11/11/2021$80.00 → $52.00Buy → Neutral
    B of A Securities
    More analyst ratings

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AI Healthcare Boom Gains Speed as Regulators and Innovators Align

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec

      5/5/25 12:35:00 PM ET
      $GEHC
      $SDGR
      $TEM
      $TVGN
      Medical Electronics
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Programming Data Processing
    • Schrödinger to Present at BofA Securities 2025 Healthcare Conference

      Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biot

      5/5/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    SEC Filings

    See more
    • SEC Form S-8 filed by Schrodinger Inc.

      S-8 - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:25:07 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Schrodinger Inc.

      10-Q - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:09:21 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:07:32 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Financials

    Live finance-specific insights

    See more
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Announce First Quarter 2025 Financial Results on May 7

      Schrödinger (NASDAQ:SDGR) will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutic

      4/23/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

      Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery Revenue of $45-50 Million in 2025 Announces Expanded Research Collaboration with Eli Lilly and Company On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. "We are delighted with Schrödinger's excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing indust

      2/26/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President of R&D, Therapeutics Akinsanya Karen exercised 16,723 shares at a strike of $3.16 and sold $419,570 worth of shares (16,723 units at $25.09) (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      4/15/25 4:31:21 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Kralingen Bridget A was granted 10,000 shares (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      3/10/25 4:35:57 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Van Kralingen Bridget A

      3 - Schrodinger, Inc. (0001490978) (Issuer)

      3/10/25 4:31:29 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Schrodinger Inc.

      SC 13G - Schrodinger, Inc. (0001490978) (Subject)

      11/13/24 4:30:25 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      2/13/24 5:13:59 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      1/23/24 11:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Schrodinger with a new price target

      Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00

      7/2/24 8:03:41 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Schrodinger with a new price target

      KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00

      12/5/23 8:08:54 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Schrodinger with a new price target

      Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00

      5/5/23 8:17:18 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

      3/10/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

      8/18/22 7:01:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru

      5/19/22 7:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care